Supplement to: Becker JC et al. Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registry. Br J Dermatol 2026
Jürgen C. Becker, Seyed Hamidreza Mahmoudpour, Dirk Schadendorf, Ulrike Leiter et autres
Table S1. Prespecified comorbid conditions and concomitant medications used to categorize patients as immunocompromised (active/ongoing at initiation of avelumab treatment)Table S2. Characteristics of patients with Merkel cell carcinoma (MCC) who received avelumab treatment by immune statusTable S3. Medical history of comorbidities in …
0 citations
Figshare